Aurinia Pharmaceuticals Inc [AUPH] stock prices are up 1.80% to $5.08 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AUPH shares have lost -0.20% over the last week, with a monthly amount drifted -2.31%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 9, April 2024, Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference. In a post published today on Yahoo Finance, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 04, 2022, when Oppenheimer downgraded its rating to a Perform. On December 10, 2021, upgrade upgraded it’s rating to Outperform and revised its price target to $31 on the stock. Oppenheimer downgraded its rating to a Perform but stick to its price target of $32 on October 28, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $35 on January 25, 2021. H.C. Wainwright reiterated a Buy rating for this stock on November 03, 2020, and downed its price target to $28. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $20 on this stock.
The stock price of Aurinia Pharmaceuticals Inc [AUPH] has been fluctuating between $4.85 and $12.43 over the past year. Currently, Wall Street analysts expect the stock to reach $16.67 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $5.08 at the most recent close of the market. An investor can expect a potential return of 228.15% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
The Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 175.51M for trailing twelve months, representing a surge of 58.59%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.44%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.2 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.00 points at the first support level, and at 4.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.14, and for the 2nd resistance point, it is at 5.19.
Aurinia Pharmaceuticals Inc [AUPH] reported earnings per share of -$0.19 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of -$0.03 and a surprise factor of -18.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.09 per share as compared to estimates of -$0.17 per share, a difference of $0.08 representing a surprise of 47.10%.
Ratios To Look Out For
It’s worth pointing out that Aurinia Pharmaceuticals Inc [NASDAQ:AUPH]’s Current Ratio is 5.50. Further, the Quick Ratio stands at 4.99, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 4.19, the price to book ratio is 1.93.
Transactions by insiders
Recent insider trading involved Greenleaf Peter, Chief Executive Officer, that happened on Mar 06 ’24 when 0.13 million shares were sold. EVP, General Counsel, Robertson Stephen P. completed a deal on Mar 06 ’24 to sell 57745.0 shares. Meanwhile, EVP, Ops & Strategy Donley Matthew Maxwell sold 40665.0 shares on Mar 06 ’24.
